64-31-3 (**硫酸盐甲醇溶液,MORPHINE SULFATE)

硫酸**;**硫酸盐;**硫酸盐甲醇;**硫酸盐甲醇溶液;

MORPHINE SULFATE ;Morphine sulfate;MORPHINE SULFATE SALT;Morphine sulfate salt solution;(-)-morphine sulfate;Avinza;Capros;Kadian;Kapanol;levo-morphine sulfate;Morphelan;morphin sulfate;morphine sulphate;NIH 0001;Oblioser;Oramorph;Relipain;Skenan;MORPHINE SULFATE (MART.);(5alpha,6alpha)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol, hydrogen sulfate (2:1);MST CONTINUS;MORPHINAN-3,6-DIOL, 7,8-DIDEHYDRO-4,5-EPOXY-17-METHYL, (5alpha,6alpha)-, SULFATE (2:1) (SALT);l-Morphine sulfate;Roxanol;MS Contin;7,8-DIDEHYDRO-4,5.ALPHA.-EPOXY-17-METHYLMORPHINAN-3,6.ALPHA.-DIOL SULFATE (2:1) (SALT);DepoDur;NIH 10753;EMBEDA COMPONENT MORPHINE SULFATE;Statex SR;MORPHINE HEMISULFATE HEMIPENTAHYDRATE;MorphaBond ER;Infumorph;Chloride, Morphine;Morphine SulfateExtended Release;MORPHINE SULFATE CII (USP-RS);MORPHINE SULFATE (AUTOINJECTOR);CHEMBL2096625;Astramorph;Morphine sulphate anhydrous;MORPHINE SULFATEEXTENDED-RELEASE;Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-(5.alpha.,6.alpha.)-, sulfate (2:1);7,8-DIDEHYDRO-4,5alpha-EPOXY-17-METHYLMORPHINAN-3,6alpha-DIOL SULPHATE (2:1) (SALT) PENTAHYDRATE;NSC-11441;Morphinan-3,6-alpha-diol, 7,8-didehydro-4, 5-alpha-epoxy-17-methyl-, sulfate;MST-1 Continus;EINECS 200-582-8;MORPHINE SULFATE ANHYDROUS [MI];MORPHINAN-3,6-DIOL, 7,8-DIDEHYDRO-4,5-EPOXY-17-METHYL-(5alpha,6alpha)-, SULFATE, HYDRATE (2:1:5);Morphine SulfateER;Morphine sulfate anhydrous;MORPHINE SULFATE (EP MONOGRAPH);MORPHINAN-3,6-DIOL, 7,8-DIDEHYDRO-4,5-EPOXY-17-METHYL, (5.ALPHA.,6.ALPHA.)-, SULPHATE (2:1) (SALT);Sulfate, Morphine;DY70C97N30;Morphine sulphate (2:1);MORPHINE SULFATE [WHO-DD];7,8-DIDEHYDRO-4,5alpha-EPOXY-17-METHYLMORPHINAN-3,6alpha-DIOL SULPHATE (2:1) (SALT);Morphine, hemisulfate;CHEBI:7003;Morphinan-3,6alpha-diol, 7,8-didehydro-4,5alpha-epoxy-17-methyl-, sulfate (2:1) (salt);7,8-DIDEHYDRO-4,5.ALPHA.-EPOXY-17-METHYLMORPHINAN-3,6.ALPHA.-DIOL SULPHATE (2:1) (SALT);Morphine sulfate,anhydrous;MSIR;Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl, (5alpha,6alpha)-, sulfate (2:1) (salt), pentahydrate;7,8-DIDEHYDRO-4,5alpha-EPOXY-17-METHYLMORPHINAN-3,6alpha-DIOL SULFATE (2:1) (SALT);MORPHINAN-3,6-DIOL, 7,8-DIDEHYDRO-4,5-EPOXY-17-METHYL, (5alpha,6alpha)-, SULPHATE (2:1) (SALT), PENTAHYDRATE;Astramorph PF;Infumorph 500;64-31-3;Oramorph SR;Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-(5alpha,6alpha)-, sulfate (2:1) (salt);17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6-diol sulfate (2:1);NSC 11441;MORPHINAN-3,6-DIOL, 7,8-DIDEHYDRO-4,5-EPOXY-17-METHYL, (5alpha,6alpha)-, SULPHATE (2:1) (SALT);Q27107392;UNII-DY70C97N30;Infumorph 200;MS CONTINCR;MITIGO;Duramorph PF;(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;sulfuric acid;Astramor PH;Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-, sulfate (2:1) (salt);MORPHINE SULFATE (USP MONOGRAPH);Arymo ER;NSC11441;SCHEMBL29316;MORPHINAN-3,6-DIOL, 7,8-DIDEHYDRO-4,5-EPOXY-17-METHYL, (5.ALPHA.,6.ALPHA.)-, SULFATE (2:1) (SALT);DTXSID4023830;Morphabond;MORPHINE SULFATE COMPONENT OF EMBEDA;Dolcontin;

USAHOPJHPJHUNS-IFCNUISUSA-N

1S/2C17H19NO3.H2O4S/c2*1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18;1-5(2,3)4/h2*2-5,10-11,13,16,19-20H,6-8H2,1H3;(H2,1,2,3,4)/t2*10-,11+,13-,16-,17-;/m00./s1

S(=O)(=O)(O)O.O1C2=C(C=CC3C[C@@H]4[C@@H]5C=C[C@@H]([C@H]1[C@@]5(C=32)CCN4C)O)O.O1C2=C(C=CC3C[C@@H]4[C@@H]5C=C[C@@H]([C@H]1[C@@]5(C=32)CCN4C)O)O